Raises FY25 revenue view to $28.3B-$28.7B, consensus $28.73B. Prior guidance was EPS $7.70-$8.10, product sales $28.2B-$28.6B.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Notable companies reporting after market close
- Gilead Sciences’ Promising Phase 2 Study on Ulcerative Colitis Treatment
- Options Volatility and Implied Earnings Moves Today, August 07, 2025
- Gilead Sciences’ Promising Phase 3 Study on Sacituzumab Govitecan for Lung Cancer
- Gilead Sciences Completes Insightful Study on Advanced Breast Cancer in Spain